和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

未开盘 01-12 16:08:30

14.480

+0.080

+0.56%

最高14.590	最低14.110	成交量83.10万
今开14.430	昨收14.400	日振幅3.33%
总市值97.31亿	流通市值97.31亿	总股本6.72亿
成交额1,193万	换手率0.12%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":14.48,"timestamp":1768205310005,"preClose":14.4,"halted":0,"volume":831034,"delay":0,"floatShares":672000000,"shares":672000000,"eps":0.04996284571544405,"marketStatus":"未开盘","change":0.08,"latestTime":"01-12 16:08:30","open":14.43,"high":14.59,"low":14.11,"amount":11925397,"amplitude":0.033333,"askPrice":14.48,"askSize":3000,"bidPrice":14.45,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.24925013193204587,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":0,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":14.4,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.653483,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2602320944","title":"和誉-B01月09日主力净流入40.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2602320944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602320944?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946506,"startTime":"0","endTime":"0","summary":"01月09日, 和誉-B股价涨0.63%，报收14.40元，成交金额1412.2万元，换手率0.15%，振幅3.56%，量比0.76。和誉-B今日主力资金净流入40.6万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.60%，主力资金累计净流入236.1万元；近20日主力资金累计净流入578.9万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161519a70662f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161519a70662f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1161","LU2476274720.SGD","02256","IE00B543WZ88.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2601350431","title":"每日卖空追踪 | 和誉-B 01月08日卖空量成交6.5万股，卖空比例为4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601350431?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861030,"startTime":"0","endTime":"0","summary":"和誉-B北京时间01月08日，跌0.56%，卖空量成交6.5万股，较上一交易日减少74.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164655a4ab44f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164655a4ab44f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274308.USD","02256","IE00B543WZ88.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","BK1161"],"gpt_icon":0},{"id":"2601388014","title":"每日卖空追踪 | 和誉-B 01月07日卖空量成交5.9万股，卖空比例为3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601388014?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774629,"startTime":"0","endTime":"0","summary":"和誉-B北京时间01月07日，涨3.82%，卖空量成交5.9万股，较上一交易日减少50.83%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163413a6fdde3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163413a6fdde3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","LU2476274308.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","02256","BK1161","LU2488822045.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2601388041","title":"和誉-B01月07日主力净流入95.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388041","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601388041?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:15","pubTimestamp":1767773709,"startTime":"0","endTime":"0","summary":"01月07日, 和誉-B股价涨3.82%，报收14.39元，成交金额2427.8万元，换手率0.25%，振幅4.47%，量比1.05。和誉-B今日主力资金净流入95.4万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.22%，主力资金累计净流入344.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入780.5万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107161538a6fdc639&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107161538a6fdc639&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","BK1161","IE00B543WZ88.USD","LU2476274308.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"1135094110","title":"和誉开曼（2256）12月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1135094110","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135094110?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:42","pubTimestamp":1767688929,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年1月6日公布截至2025年12月31日的股份变动月报表。公告显示，公司注册股本维持在5,000,000,000股，面值每股USD 0.00001，总额USD 50,000，与上月一致。根据公告，公司于本月无任何新增发行、转让或注销活动，股本维持稳定。此前于2025年3月与4月购回合计2,485,000股尚未注销，其状态截至2025年12月31日保持不变。公司同时表示，持续遵守香港联交所《上市规则》等相关法规。本次公告由执行董事及联席公司秘书喻红平签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"gpt_icon":0},{"id":"2601866281","title":"【券商聚焦】天风证券维持和誉-B(02256)“买入”评级 指公司在研管线储备丰厚","url":"https://stock-news.laohu8.com/highlight/detail?id=2601866281","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601866281?lang=zh_cn&edition=full","pubTime":"2026-01-06 14:26","pubTimestamp":1767680785,"startTime":"0","endTime":"0","summary":"对照组患者改用匹米替尼后，同样获得临床获益，中位随访时间8.5个月时，ORR达到64.5%，COAs也有所改善。默克于2025年4月行权，获得全球商业化权益，行权费用为8500万美元。公司在研管线储备丰厚，已构建 10余条处于临床阶段的肿瘤产品管线，Pan-KRAS inhibitor ABSK211预计2026年进入临床阶段，FGFR4抑制剂ABSK011等药物的研发正在顺利推进中。维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972675","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256","601162"],"gpt_icon":0},{"id":"2601884019","title":"每日卖空追踪 | 和誉-B 01月05日卖空量成交6.1万股，卖空比例为3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601884019?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601828,"startTime":"0","endTime":"0","summary":"和誉-B北京时间01月05日，涨5.38%，卖空量成交6.1万股，较上一交易日增加24.49%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163610a49e2a20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163610a49e2a20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1161","LU2476274720.SGD","02256","IE00B543WZ88.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2601840548","title":"和誉-B01月05日获主力加仓100.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601840548","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601840548?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:15","pubTimestamp":1767600938,"startTime":"0","endTime":"0","summary":"01月05日, 和誉-B股价涨5.38%，报收13.72元，成交金额2399.0万元，换手率0.26%，振幅10.60%，量比0.95。和誉-B今日主力资金净流入100.2万元，连续5日净流入，上一交易日主力净流入63.7万元。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为66.67%，平均涨幅为4.61%。该股近5个交易日上涨2.54%，主力资金累计净流入331.6万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入865.9万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161851a6f51075&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161851a6f51075&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","IE00B543WZ88.USD","02256","BK1161","LU2476274720.SGD","LU2476274308.USD"],"gpt_icon":0},{"id":"2601884774","title":"和誉-B盘中异动 早盘股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601884774?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:22","pubTimestamp":1767579750,"startTime":"0","endTime":"0","summary":"2026年01月05日早盘10时22分，和誉-B股票出现异动，股价急速上涨5.45%。截至发稿，该股报13.730港元/股，成交量52.3万股，换手率0.08%，振幅8.60%。和誉-B股票所在的生物技术行业中，整体涨幅为3.25%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105102230a49cdde0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105102230a49cdde0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU2476274308.USD","LU2778985437.USD","02256","BK1161","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2601884091","title":"和誉-B：匹米替尼获批上市 正式迈入商业化阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884091","media":"天风证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601884091?lang=zh_cn&edition=full","pubTime":"2026-01-05 00:00","pubTimestamp":1767542400,"startTime":"0","endTime":"0","summary":"事件CSF-1R 高选择性小分子匹米替尼获批上市，用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤患者。首个自研创新药产品匹米替尼获批上市，具备BIC 潜力匹米替尼是公司首个获批上市的自研创新药产品，疗效和安全性良好。对照组患者改用匹米替尼后，同样获得临床获益，中位随访时间8.5 个月时，ORR 达到64.5%，COAs 也有所改善。公司与默克就匹米替尼在2023 年订立独家许可协议，默克获得匹米替尼中国地区的商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105143638a49db01e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105143638a49db01e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2476274308.USD","IE00B543WZ88.USD","BK1161","LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","02256"],"gpt_icon":0},{"id":"2600062285","title":"每日卖空追踪 | 和誉-B 01月02日卖空量成交1.5万股，卖空比例为1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600062285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600062285?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342629,"startTime":"0","endTime":"0","summary":"和誉-B北京时间01月02日，涨0.08%，卖空量成交1.5万股，较上一交易日减少85.58%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163316a6eb2a30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163316a6eb2a30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1161","LU2476274720.SGD","02256","IE00B543WZ88.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2600062405","title":"和誉-B01月02日获主力加仓63.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600062405","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600062405?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:15","pubTimestamp":1767341757,"startTime":"0","endTime":"0","summary":"01月02日, 和誉-B股价涨0.08%，报收13.02元，成交金额1412.5万元，换手率0.16%，振幅2.54%，量比0.60。和誉-B今日主力资金净流入63.7万元，连续4日净流入，上一交易日主力净流入85.1万元。该股近5个交易日下跌3.13%，主力资金累计净流入191.6万元；近20日主力资金累计净流入726.6万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102162007a4942359&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102162007a4942359&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","BK1161","IE00B543WZ88.USD","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2778985437.USD","02256"],"gpt_icon":0},{"id":"2600818700","title":"【券商聚焦】西部证券维持和誉-B“买入”评级 指匹米替尼开启全球商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2600818700","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600818700?lang=zh_cn&edition=full","pubTime":"2025-12-31 10:48","pubTimestamp":1767149329,"startTime":"0","endTime":"0","summary":"）获NMPA批准上市，成为中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物，其全球商业化权益由默克负责。当前股价12.9港元，维持\"买入\"评级。研发管线方面，除已获批的匹米替尼外，KRAS G12D抑制剂ABSK141在12月初获FDA IND批准，PD-L1抑制剂ABSK043联合疗法II期临床显示可控安全性。主要风险包括商业化进度不及预期、临床开发延迟及海外上市受阻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231114718a48ccf37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231114718a48ccf37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256"],"gpt_icon":0},{"id":"2595796611","title":"引领中国创新药全球多中心同步临床开发新实践——访和誉医药董事长徐耀昌","url":"https://stock-news.laohu8.com/highlight/detail?id=2595796611","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595796611?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:22","pubTimestamp":1767090149,"startTime":"0","endTime":"0","summary":"近日，和誉医药（02256.HK）自主研发的一类新药贝捷迈（盐酸匹米替尼胶囊）获国家药品监督管理局批准上市，填补了国内腱鞘巨细胞瘤（TGCT）系统疗法的临床空白。《经济参考报》记者走进和誉医药，探寻在这场里程碑式的突破背后，和誉医药董事长兼CEO徐耀昌博士带领团队，用科学坚守与务实创新，书写了中国医药产业高质量发展的“生动答卷”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605811750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","LU2778985437.USD","LU2476274308.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","159992","02256","159938","BK1574","LU2476274720.SGD","BK1161","BK1515","LU2488822045.USD","IE00BPRC5H50.USD","06978"],"gpt_icon":0},{"id":"2595725535","title":"每日卖空追踪 | 和誉-B 12月30日卖空量成交5.5万股，卖空比例为2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595725535?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:30","pubTimestamp":1767083428,"startTime":"0","endTime":"0","summary":"和誉-B北京时间12月30日，涨1.63%，卖空量成交5.5万股，较上一交易日减少63.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163414a4897ec8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163414a4897ec8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU2476274308.USD","LU2778985437.USD","02256","BK1161","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2595255367","title":"和誉-B12月30日获主力加仓85.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595255367","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595255367?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:15","pubTimestamp":1767082518,"startTime":"0","endTime":"0","summary":"12月30日, 和誉-B股价涨1.63%，报收13.11元，成交金额2889.3万元，换手率0.33%，振幅3.26%，量比1.46。和誉-B今日主力资金净流入85.1万元，连续3日净流入，上一交易日主力净流入32.6万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为62.50%，平均涨幅为4.35%。该股近5个交易日下跌2.74%，主力资金累计净流入150.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入662.9万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230161602a48969e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230161602a48969e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","IE00B543WZ88.USD","LU2488822045.USD","IE00BPRC5H50.USD","02256","LU2778985437.USD","BK1161","LU2476274308.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2595619647","title":"每日卖空追踪 | 和誉-B 12月29日卖空量成交5.4万股，卖空比例为3.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595619647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595619647?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997027,"startTime":"0","endTime":"0","summary":"和誉-B北京时间12月29日，跌3.59%，卖空量成交5.4万股，较上一交易日减少32.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163356a4854a17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163356a4854a17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","02256","BK1161","LU2476274308.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2778985437.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2595684204","title":"申万宏源：维持和誉-B(02256)“买入”评级 首款自研新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2595684204","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595684204?lang=zh_cn&edition=full","pubTime":"2025-12-29 13:58","pubTimestamp":1766987921,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，12月22日，和誉-B公告，CSF-1R抑制剂匹米替尼获中国药监局批准上市，用于手术切除可能会导致功能受限或出现较严重并发症的症状性腱鞘巨细胞瘤成年患者。首款自研新药获批上市，开启商业化新征程，同时在研管线稳步推进，实现“自我造血”的良性循环，维持“买入”评级。凭借匹米替尼在产品力上差异化的优势，以及默克强大的全球商业化能力，该行看好该产品上市后的放量情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000166","02256"],"gpt_icon":0},{"id":"2593447842","title":"中金：维持和誉-B(02256)跑赢行业评级 目标价20港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593447842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593447842?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:12","pubTimestamp":1766538771,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持和誉-B2025年/2026年归母净利润预测0.48亿元/3.20亿元不变。根据DCF模型，该行维持跑赢行业评级和目标价20港币不变，较当前股价有48.8%的上行空间。匹米替尼获批速度超该行预期，临床证据确凿2025年6月，公司公告匹米替尼在中国的上市申请获得受理，到如今获批仅用了6个多月。该行期待匹米替尼商业化为公司带来新的动能。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256"],"gpt_icon":0},{"id":"2593418484","title":"和誉-B(02256)：口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418484","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418484?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:02","pubTimestamp":1766534531,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141用于治疗携带KRAS G12D突变的晚期实体瘤患者的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B543WZ88.USD","LU2476274308.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","IE00BPRC5H50.USD","IND","BK1161","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0554},{"period":"1month","weight":0.0112},{"period":"3month","weight":-0.0736},{"period":"6month","weight":0.4836},{"period":"1year","weight":2.2909},{"period":"ytd","weight":0.113}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.3957},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.091811},{"month":2,"riseRate":0.75,"avgChangeRate":0.046576},{"month":3,"riseRate":0.5,"avgChangeRate":0.054417},{"month":4,"riseRate":0.25,"avgChangeRate":-0.010041},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}